YU8004A - Vakcina protiv bolesti zapadnog nila - Google Patents

Vakcina protiv bolesti zapadnog nila

Info

Publication number
YU8004A
YU8004A YU8004A YUP8004A YU8004A YU 8004 A YU8004 A YU 8004A YU 8004 A YU8004 A YU 8004A YU P8004 A YUP8004 A YU P8004A YU 8004 A YU8004 A YU 8004A
Authority
YU
Yugoslavia
Prior art keywords
west nile
vaccine
provides
disease
vaccine composition
Prior art date
Application number
YU8004A
Other languages
English (en)
Inventor
Hsien-Jue Chu
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of YU8004A publication Critical patent/YU8004A/sh
Publication of RS53184B publication Critical patent/RS53184B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prikazani pronalazak obezbeđuje sigurnu i efikasnu kompoziciju vakcine protiv virusne bolesti zapadnog Nila. Imunogeno aktivna komponenta virusa zapadnog Nila ili plazmida DNK, pomoćne supstance kao što je ulje koje se metabolizuje i farmakološki prihvatljivog nosača je formulisano u imunizirajući vakcinu. Pronalazak takođe obezbeđuje postupak za sprečavanje ili ublažavanje bolesti zapadnog Nila, kao što je encefalitis kod ekvida davanjem kompozicije vakcine koja je ovde izložena.[The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.
YU8004A 2001-07-27 2002-07-23 Kompozicija vakcine za primenu u sprečavanju ili ublažavanju encefalitisa zapadnog nila kod ekvida RS53184B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
YU8004A true YU8004A (sh) 2006-08-17
RS53184B RS53184B (sr) 2014-06-30

Family

ID=27613166

Country Status (24)

Country Link
US (8) US7153513B2 (sh)
EP (3) EP2283858A3 (sh)
JP (2) JP4718778B2 (sh)
KR (2) KR20040028952A (sh)
CN (2) CN1273189C (sh)
AU (1) AU2002365244B2 (sh)
BE (1) BE2014C006I2 (sh)
BR (1) BRPI0211492B1 (sh)
CA (1) CA2452545C (sh)
CY (1) CY2014010I2 (sh)
DK (1) DK1427444T3 (sh)
ES (1) ES2435095T3 (sh)
FR (1) FR14C0016I2 (sh)
HR (1) HRP20040195B1 (sh)
HU (2) HU228690B1 (sh)
LU (1) LU92348I2 (sh)
ME (1) ME00491B (sh)
MX (1) MXPA04000680A (sh)
NZ (3) NZ570270A (sh)
PL (2) PL220846B1 (sh)
PT (1) PT1427444E (sh)
RS (1) RS53184B (sh)
WO (1) WO2003061555A2 (sh)
ZA (1) ZA200401596B (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
AU2002365244B2 (en) * 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
WO2005024427A2 (en) * 2003-09-09 2005-03-17 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
CA2601705A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
BRPI0611581B1 (pt) 2005-06-24 2021-08-03 Intervet International B.V. Flavivírus quimérico inativado, composição imunogênica, e, vacina
AU2006304747B2 (en) * 2005-10-19 2013-10-03 Cornell Research Foundation, Inc. Influenza viruses able to infect canids, uses thereof
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
CN104043116A (zh) * 2007-11-06 2014-09-17 硕腾W有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9642908B2 (en) * 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
AU2009287449B2 (en) 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
MX2012004133A (es) * 2009-10-07 2012-05-08 Wyeth Llc Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
EP2996719B1 (en) * 2013-05-14 2019-06-26 Zoetis Services LLC Novel vaccine compositions comprising immunostimulatory oligonucleotides
AU2014315353A1 (en) * 2013-09-05 2016-03-10 Zoetis Services Llc Hendra and Nipah virus G glycoprotein immunogenic compositions
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
EP3930749A1 (en) 2019-02-27 2022-01-05 University of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US7417136B1 (en) 1998-06-04 2008-08-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
EP1322338A4 (en) 2000-10-04 2005-04-13 Univ Pennsylvania COMPOSITIONS AND METHODS OF USING A CAPSID PROTEIN FROM VARIOUS FLAVIVIRUS AND PESTIVIRUS
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
CA2440593A1 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AU2002365244B2 (en) * 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
WO2004016586A2 (en) 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
CA2452545C (en) 2015-06-09
US20070166324A1 (en) 2007-07-19
JP2005515236A (ja) 2005-05-26
BE2014C006I2 (sh) 2021-02-04
LU92348I2 (fr) 2014-09-22
LU92348I9 (sh) 2019-01-02
PL368535A1 (en) 2005-04-04
HUP0401606A3 (en) 2005-02-28
ES2435095T3 (es) 2013-12-18
CN1273189C (zh) 2006-09-06
PL212212B1 (pl) 2012-08-31
DK1427444T3 (da) 2013-11-04
JP2011057692A (ja) 2011-03-24
EP1427444A4 (en) 2008-01-02
WO2003061555A2 (en) 2003-07-31
HUP0401606A2 (hu) 2004-11-29
MXPA04000680A (es) 2004-04-05
HRP20040195B1 (hr) 2014-07-18
US7648706B2 (en) 2010-01-19
HRP20040195A2 (en) 2004-08-31
US7153513B2 (en) 2006-12-26
BRPI0211492B1 (pt) 2016-06-21
US20070231349A1 (en) 2007-10-04
ME00491B (me) 2011-10-10
KR20040028952A (ko) 2004-04-03
PL220846B1 (pl) 2016-01-29
CN1935258B (zh) 2013-04-03
US20070166802A1 (en) 2007-07-19
WO2003061555A3 (en) 2004-04-15
CY2014010I1 (el) 2020-05-29
EP2283858A3 (en) 2011-03-23
AU2002365244B2 (en) 2007-12-06
EP2283858A2 (en) 2011-02-16
PL398575A1 (pl) 2012-06-18
FR14C0016I2 (fr) 2015-07-24
HK1066470A1 (en) 2005-03-24
US20070166326A1 (en) 2007-07-19
NZ570270A (en) 2010-08-27
FR14C0016I1 (sh) 2014-03-28
NZ531265A (en) 2008-08-29
CN1935258A (zh) 2007-03-28
HUS1300055I1 (hu) 2016-08-29
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
CA2452545A1 (en) 2003-07-31
BR0211492A (pt) 2004-08-17
PT1427444E (pt) 2013-11-19
US20070231350A1 (en) 2007-10-04
EP2281572A1 (en) 2011-02-09
CN1535157A (zh) 2004-10-06
HU228690B1 (en) 2013-05-28
CY2014010I2 (el) 2024-02-16
ZA200401596B (en) 2005-07-27
NZ553165A (en) 2008-09-26
US20030091595A1 (en) 2003-05-15
JP4718778B2 (ja) 2011-07-06
US7445787B2 (en) 2008-11-04
US20070178119A1 (en) 2007-08-02
US7648705B2 (en) 2010-01-19
RS53184B (sr) 2014-06-30
KR20090053967A (ko) 2009-05-28
US20070166325A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
MXPA04000680A (es) Vacuna para virus west nile.
GB0025577D0 (en) Vaccine
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
DE60210456D1 (de) Solubisierung von kapseln polysacchariden
WO2002009643A3 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
CA2189979A1 (en) Improved modified live brsv vaccine
WO2004045529A3 (en) West nile virus vaccine
IL154913A0 (en) Composition comprising immunogenic microparticles
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
WO2004098491A3 (en) METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
CY1112120T1 (el) Ενα εμβολιο σκυλου για προστασια απο την ερλιχιωση
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2003059385A3 (en) Hiv vaccine and method of use
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
WO2003051288A3 (en) Mycobacterial vaccine
MXPA02010173A (es) Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis.
WO2002028362A3 (fr) Composition vaccinale et procede de stabilisation
MY153290A (en) Multivalent avian influenza vaccines
WO2002009749A3 (en) Respiratory syncytial virus vaccine
MXPA05009447A (es) Vacunas bovinas con adyuvante.
WO2001064244A3 (en) In ovo protection against infectious bronchitis
SG147465A1 (en) Vaccine
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
WO2003030935A3 (en) Adjuvants for nucleic acid vaccines
PL348550A1 (en) Ibdv mutant, vaccine containing it for protecting poultry against a disease caused by ibdv and method of protecting poultry against such disease